Stay Informed with Genetis
Explore the latest updates on our initiatives, partnerships, and industry advancements. Learn how Genetis is shaping the future of vaccine development in Australia and beyond
-
Technovalia, Sypharma and BioNet announce the establishment of Genetis, the first Australian Vaccine Development and Manufacturing Hub for mRNA, DNA and recombinant vaccines.
Establishment of the first end-to-end Australian capability for product development and commercial scale production of mRNA, DNA and recombinant vaccines By bringing together the technology, product development, GMP manufacturing, clinical and regulatory expertise of key consortium partners Technovalia, Sypharma and BioNet, Genetis will provide a unique Australian-based vaccine contract and product development manufacturing hub for Australian and offshore research organisations seeking access to quality capability and TGA approved products. The founding partners have …